#GileadNews: Today, we completed our acquisition of Tubulis, further strengthening our oncology portfolio with a next‑generation ADC platform and clinical‑stage programs with broad potential across multiple tumor types. This milestone builds on the most diverse pipeline in our company’s history and positions us to help more people touched by cancer. Learn more: https://gilead.inc/3RCuZpf
Gilead Sciences
Исследования в сфере биотехнологий
Foster City, CA 822 551 отслеживающий
О нас
At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines
- Веб-сайт
-
http://www.gilead.com
Внешняя ссылка для организации Gilead Sciences
- Отрасль
- Исследования в сфере биотехнологий
- Размер компании
- Более 10 000 сотрудников
- Штаб-квартира
- Foster City, CA
- Тип
- Публичная компания
Местоположения
Сотрудники Gilead Sciences
Обновления
-
Earlier this month, Gilead employees volunteered with Stephen and Ayesha Curry's Eat. Learn. Play. Foundation, coming together to help build a new school yard at the Oakland Academy of Knowledge (OAK). Team members spent the day painting, assembling playground equipment and working to create a safe, fun play area for students. The Eat. Learn. Play. Foundation is one of the Gilead Foundation’s valued community partners, and we're proud to support its mission to increase kids’ access to nutritious food, learning resources and outlets for play. Efforts like these reflect our shared commitment to helping build healthier, stronger communities where children can thrive. #EatLearnPlay #PlayspaceEquity
-
-
Manufacturing is where CAR T becomes real. Every therapy is made-to-order. Every step in the process has to be done right, the first time. And every single day matters. Our promise is fast and reliable CAR T manufacturing for patients no matter where they are. Because we know patients don't have time to wait. Watch to learn how CAR T-cell therapy helps deliver hope to patients. https://gilead.inc/4uPBZgM
Learn how CAR T-cell therapy helps deliver hope to patients
-
The first treatment decision after a metastatic triple-negative breast cancer diagnosis can shape everything that follows. Hear why access to the most effective treatment options is essential, especially for those disproportionately impacted like young women and Black and Brown communities.
The urgency in metastatic TNBC
-
At Gilead, we’re committed to advancing #HIV prevention as an essential part of overall public health. Jared Baeten, MD, speaks to this commitment by highlighting why HIV prevention within the broader context of individual and community health matters. This approach helps support more effective, equitable solutions and drive real impact.
-
With her journalistic instinct and personal experience with breast cancer, Athena Jones is devoted to providing clarity for those navigating metastatic triple-negative breast cancer (mTNBC). Listen to her conversation with oncology nurse Caroline Koffke, RN, BSN, OCN to learn more about innovations in the treatment of mTNBC. Thank you both for your commitment to helping patients navigate the most aggressive type of breast cancer.
#GileadPartner #ad A Candid Conversation About Metastatic TNBC Metastatic triple-negative breast cancer is the most aggressive subtype of breast cancer. I spoke with Caroline Koffke, RN, BSN, OCN, a breast cancer nurse and advocate, about scientific advancements in treating mTNBC and what makes her most hopeful when it comes to battling this difficult-to-treat form of breast cancer. For more information on TNBC, visit: https://lnkd.in/ew-UXXKr
-
We’re proud to share that Daniel O'Day, our Chairman & CEO, was recently honored by his alma mater Columbia Business School for his values-driven leadership and the lasting impact he has made on society. It is a recognition that mirrors what has guided Gilead for nearly four decades: when leadership is rooted in genuine purpose, it moves through an organization and out into the world in ways that matter.
-
-
By sharing lived experiences of #viralhepatitis, we can broaden understanding and surface unspoken realities. Introducing Dee and Imee! Our newest Ambassadors for the BehinD the SilenCe campaign, created in collaboration with The World Hepatitis Alliance (WHA) to shine a light on how stigma affects people living with viral hepatitis and encourage more open doctor-patient conversations Dee and Imee are passionate advocates for change, sharing their stories with hope and courage. Listen to their stories and learn more at https://gilead.inc/4tT36rn
-
#GileadNews: Today, we released our first quarter 2026 financial results. https://gilead.inc/4w7cJEi #Earnings
-
This April, Gilead celebrated ADAPT’s first-ever Heritage Month, highlighting disability inclusion as a catalyst for innovation, belonging, and impact. Through powerful conversations, learning experiences, and engagement across global chapters, employees came together to build community and drive change—expanding ADAPT’s reach and surpassing our Giving Together goal in support of Canine Companions. As Executive Sponsor Johanna Mercier shared: “When people can contribute fully and equally, teams are stronger and the impact is greater.”
-
Аффилированные страницы
Похожие страницы
Финансирование
Gilead Sciences
Всего 5 раундов
См. дополнительные сведения в Crunchbase
Последний раунд
Долг после первичного публичного размещения акций
Внешняя ссылка на Crunchbase для последнего раунда финансирования
3 500 000,00 $